BEDMINSTER, N.J.--(BUSINESS WIRE)--Nov. 7, 2012--
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the
Lazard Capital Markets 9th Annual Healthcare Conference in
New York on Wednesday, November 14, 2012 at 9:30 a.m. ET and the
Jefferies 2012 Global Healthcare Conference in London Thursday, November
15, 2012 at 10:00 a.m. WET. Presentations will be available as live
webcasts with replays available approximately three hours after the
presentations have concluded. Interested parties may access the webcast
from the investors’ calendar of events page on the NPS website at http://www.npsp.com/page/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing
orphan products to patients with rare disorders and few, if any,
therapeutic options. NPS is advancing two late-stage registration
programs. A New Drug Application is undergoing FDA review for Gattex®
(teduglutide) as a treatment for adults with short bowel syndrome (SBS)
and a Biologic License Application is being prepared for Natpara®
(rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline
includes two calcilytic compounds, NPSP790 and NPSP795, with potential
application in rare disorders involving increased calcium receptor
activity, such as autosomal dominant hypocalcemia with hypercalciuria
(ADHH). NPS complements its proprietary programs with a royalty-based
portfolio of products and product candidates that includes agreements
with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin,
and Nycomed, a Takeda company.
Source: NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
